New dengue vaccine TAK-003 gains WHO prequalification for high-burden areas

FHS
May 20, 2024
8:07 am

A new vaccine for dengue received prequalification from the World Health Organization (WHO) on 10 May 2024. TAK-003 is the second dengue vaccine to be prequalified by WHO. Developed by Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.

How a patient helped shape a treatment for a rare skin disorder – Pharmaceutical Technology

Dr Jasmin Barman-Aksӧzen speaking at the Outsourcing in Clinical Trials (OCT) DACH 2024 conference in Zurich, Switzerland. Credit: Jenna Philpott / GlobalData. When Dr Jasmin

October 30, 2024

Why the world’s most expensive drug might not be all that overpriced

The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge

March 28, 2024

BioCardia unveils interim data that led it to stop PhIII enrollment of heart failure stem cell therapy

BioCardia disclosed that its heart failure stem cell therapy failed to hit on all three measures that comprised the primary endpoint of a Phase III

September 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.